SOURCE: Hutchison China Meditech Limited

November 30, 2016 03:40 ET

Hutchison China Meditech Limited: Total Voting Rights

HONG KONG, CHINA--(Marketwired - Nov 30, 2016) - Hutchison China Meditech Limited (NASDAQ: HCM) (AIM: HCM)

AIM/Nasdaq: HCM

Total Voting Rights

London: Wednesday, November 30, 2016: For information purposes, Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) hereby notifies the market that as at November 30, 2016, the issued share capital of Chi-Med consisted of 60,703,323 ordinary shares of US$1.00 each, with each share carrying one right to vote and with no shares held in treasury.

The above figure of 60,703,323 may be used by shareholders as the denominator for the calculations by which they could determine if they are required to notify their interest in, or a change to their interest in, Chi-Med under the Financial Conduct Authority's Disclosure Rules and Transparency Rules.

For illustrative purposes only, the 60,703,323 ordinary shares would be equivalent to 60,703,323 CREST depositary interests (each equating to one ordinary share) which are traded on AIM or, if the CREST depositary interests were converted in their entirety, equivalent to 121,406,646 American depositary shares (each equating to one-half of one ordinary share) which are traded on Nasdaq.

About Chi-Med

Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.

Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: www.chi-med.com.

Contacts

Investor Enquiries    
Christian Hogg, CEO +852 2121 8200  
     
International Media Enquiries    
Anthony Carlisle, +44 7973 611 888  
Citigate Dewe Rogerson (Mobile) anthony.carlisle@cdrconsultancy.co.uk
     
U.S. Based Media Enquiries    
Brad Miles, +1 (917) 570 7340  
BMC Communications (Mobile) bmiles@bmccommunications.com
     
Susan Duffy, +1 (917) 499 8887  
BMC Communications (Mobile) sduffy@bmccommunications.com
     
Investor Relations    
Matt Beck, +1 (917) 415 1750  
The Trout Group (Mobile) mbeck@troutgroup.com
     
David Dible, +44 7967 566 919  
Citigate Dewe Rogerson (Mobile) david.dible@citigatedr.co.uk
     
Panmure Gordon (UK) Limited    
Richard Gray / +44 (20) 7886 2500  
Andrew Potts

Contact Information